Two patient‐derived xenograft models of type 2 diabetes (T2D) with xenografted colon tumors under high glucose concentrations, including the C57BL/6 and the BALB/c nude mouse model, have provided further evidence that inhibiting the LINRIS/IGF2BP2/MYC axis effectively suppresses cancer growth without notable side effects, indicating a potential treatment approach for CRC.355. This evidence concerns the gene IGF2BP2 and colorectal carcinoma.